Table 1.
Baseline characteristics of included studies for meta-analysis.
| First author, year | Number of cases |
Age (y, Intervention/Control) | Type of surgery | Dose of NMBA | Additional NMBA | Intervention | Control | Time to reverse | |
|---|---|---|---|---|---|---|---|---|---|
| Intervention | Control | ||||||||
| Yang LL, 2021 [18] | 30 | 30 | 6.50 ± 2.60/6.70 ± 3.10 | Otolaryngology surgery | 0.6 mg/kg Roc | 0.2 mg/kg Roc as needed | 2 mg/kg Sug | 30 μg/kg Neo + 10μg/kg Atp | TOFR ≥0.1 |
| Hu J, 2020 [19] | 20 | 20 | 2.67 ± 1.75/3.00 ± 1.67 | Laparoscopic hernia repair | 0.6 mg/kg Roc | 0.1 mg/kg Roc as needed | 2 mg/kg Sug | 50 μg/kg Neo + 10 μg/kg Atp | Reappearance of T2 |
| Huang L, 2022 [20] | 20 | 20 | 2.58 ± 0.90/2.76 ± 1.00 | Heart surgery | 1.0 mg/kg/h Roc | – | 2 mg/kg Sug | 40 μg/kg Neo + 20 μg/kg Atp | PTC = 1-2 |
| Jiang Y, 2020 [21] | 30 | 30 | 3–6 years | Tonsillectomy | 0.6 mg/kg Roc | 0.8–1.0 mg/kg/h Roc | 2 mg/kg Sug | 40 μg/kg Neo + 20 μg/kg Atp | Reappearance of T2 |
| Veiga RG, 2011 [22] | 14 | 10 | 4.80 ± 2.10/4.30 ± 2.30 | Unclear | 0.45 mg/kg Roc | 0.15 mg/kg Roc as needed | 2 mg/kg Sug | 50 μg/kg Neo + 25 μg/kg Atp | Reappearance of T2 |
| Kara T, 2014 [23] | 40 | 40 | 6.48 ± 2.81/5.07 ± 3.24 | Lower abdominal or urogenital procedures | 0.6 mg/kg Roc | 0.2 mg/kg Roc as needed | 2 mg/kg Sug | 30 μg/kg Neo + 10μg/kg Atp | Reappearance of T2 |
| Voss T, 2022 [24] | 242 | 34 | 7.70 ± 4.60/8.50 ± 4.30 | Unclear | – | – | 2 and 4 mg/kg Sug | 50 μg/kg Neo + 10–30 μg/kg Atp | Reappearance of T2 |
| Plaud B, 2009 [25] | 23 | 6 | 2–17 years | Surgery in a supine position | 0.6 mg/kg Roc | None | 2 and 4 mg/kg Sug | none description | Reappearance of T2 |
| Ji SH, 2022 [26] | 30 | 10 | 3.5–16 years | Brain and spine surgery | 1.0 mg/kg Roc | None | 2, 4 and 8 mg/kg Sug | 30 μg/kg Neo | Reappearance of T2 |
| Saber H, 2021 [27] | 25 | 25 | 0.77 ± 0.60/0.62 ± 0.58 | Cardiac catheterization | 0.6 mg/kg Roc | 0.2 mg/kg Roc per 20 min | 4 mg/kg Sug | 40 μg/kg Neo + 20 μg/kg Atp | Reappearance of T2 |
| Alvarez-Gomez JA, 2012 [28] | 49 | 47 | 4.98 ± 2.07/4.86 ± 2.23 | Unclear | 0.6 mg/kg Roc | – | 4 mg/kg Sug | 50 μg/kg Neo + 25 μg/kg Atp | PTC <2 |
| EI Sayed M, 2016 [29] | 35 | 35 | 5.64 ± 2.41/5.42 ± 2.23 | Tonsillectomy | 0.6 mg/kg Roc | 0.2 mg/kg Roc as needed | 2 mg/kg Sug | 50 μg/kg Neo + 10 μg/kg Atp | Reappearance of T2 |
| An J, 2020 [30] | 30 | 30 | 6.49 ± 2.20/6.47 ± 2.29 | Entropion surgery | 0.6 mg/kg Roc | 0.2 mg/kg Roc was administered after the first 40 min | 2 mg/kg Sug | 20 μg/kg Pyr+ 10 μg/kg Gyl | TOFR ≥0.1 |
| Güzelce D, 2016 [31] | 16 | 21 | 6.37 ± 4.08/7.02 ± 4.46 | Lower urinary tract surgery and inguinal hernia | 0.6 mg/kg Roc | 0.15 mg/kg Roc as needed | 2 mg/kg Sug | 50 μg/kg Neo + 20 μg/kg Atp | Reappearance of T2 |
| Ozgun C, 2014 [32] | 30 | 30 | 7.30 ± 2.20/8.00 ± 2.80 | Ear nose and throat surgery | 0.6 mg/kg Roc | 0.1–0.2 mg/kg Roc as needed | 2 mg/kg Sug | 60 μg/kg Neo + 20 μg/kg Atp | Reappearance of T2 |
| Ghoneim A, 2015 [33] | 20 | 20 | 11.1 ± 3.45/10.9 ± 2.23 | Posterior fossa tumor excision | 0.6 mg/kg Roc | 0.4 mg/kg Roc as needed | 4 mg/kg Sug | 40 μg/kg Neo + 20 μg/kg Atp | Reappearance of T2 |
| Mohamad Zaini RH, 2016 [34] | 40 | 40 | 2–12 years | Unclear | 0.6 mg/kg Roc | 0.2 mg/kg Roc as needed | 2 mg/kg Sug | 50 μg/kg Neo + 10 μg/kg Atp | Reappearance of T2 |
| Ammar AS, 2017 [35] | 30 | 30 | 7.80 ± 2.20/8.00 ± 2.40 | Lower abdominal surgery | 0.6 mg/kg Roc | 0.1 mg/kg Roc was administered when TOF count becomes ≥1 | 4 mg/kg Sug | 35 μg/kg Neo + 20 μg/kg Atp | Sug group: PTC = 1–2; Control group: Reappearance of T2 |
Abbreviation: y = year; NMBA = neuromuscular blocking agents; Roc = rocuronium; Sug = sugammadex; Neo = neostigmine; Atp = atropine; TOFR = train of four stimulation ratio; PTC = post-tetanic count.